Mavacamten

Last Updated: 06/30/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 556 publications

Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy.

Mavacamten in Nonobstructive Hypertrophic Cardiomyopathy.

Journal: The New England journal of medicine

Published: June 17, 2026

Mavacamten toxicity, hepatic dysfunction, and rifampicin: cause or coincidence?

Mavacamten toxicity, hepatic dysfunction, and rifampicin: cause or coincidence?

Journal: European heart journal. Case reports

Published: June 15, 2026

A global model for symptomatic obstructive hypertrophic cardiomyopathy to assess the cost-effectiveness of mavacamten: results from a Dutch societal perspective.

A global model for symptomatic obstructive hypertrophic cardiomyopathy to assess the cost-effectiveness of mavacamten: results from a Dutch societal perspective.

Journal: Journal of medical economics

Published: June 08, 2026

Modeling Hypertrophic Cardiomyopathy-Related MYH7 Variants: Insights into Structural Changes and Cardiovascular Drug-Binding Affinities.

Modeling Hypertrophic Cardiomyopathy-Related MYH7 Variants: Insights into Structural Changes and Cardiovascular Drug-Binding Affinities.

Journal: Biological & pharmaceutical bulletin

Published: May 27, 2026

Long-Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER-CN Study.

Long-Term Efficacy and Safety of Mavacamten in Chinese Patients With Obstructive Hypertrophic Cardiomyopathy: Week 78 Results From the EXPLORER-CN Study.

Journal: Journal of the American Heart Association

Published: May 25, 2026

Grapefruit-Mavacamten Interaction Leading to Reduced Ejection Fraction: When Energy Drinks Aren't So Energizing.

Grapefruit-Mavacamten Interaction Leading to Reduced Ejection Fraction: When Energy Drinks Aren't So Energizing.

Journal: JACC. Case reports

Published: May 18, 2026

Aficamten (Myqorzo) for obstructive hypertrophic cardiomyopathy.

Aficamten (Myqorzo) for obstructive hypertrophic cardiomyopathy.

Journal: The Medical letter on drugs and therapeutics

Published: May 15, 2026

Paradoxical Rise in Pulmonary Artery Pressure Following Successful Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy: A Case Report.

Paradoxical Rise in Pulmonary Artery Pressure Following Successful Mavacamten Therapy for Obstructive Hypertrophic Cardiomyopathy: A Case Report.

Journal: Clinical case reports

Published: May 09, 2026

The ODYSSEY-HCM and MAPLE-HCM studies: the role of cardiac myosin inhibitors in hypertrophic cardiomyopathy (obstructive and non-obstructive).

The ODYSSEY-HCM and MAPLE-HCM studies: the role of cardiac myosin inhibitors in hypertrophic cardiomyopathy (obstructive and non-obstructive).

Journal: European heart journal supplements : journal of the European Society of Cardiology

Published: May 08, 2026

Myosin ATPase Inhibition Relieves the Energetic Burden in Skeletal Myofibres of Patients With Heart Failure With Reduced Ejection Fraction.

Myosin ATPase Inhibition Relieves the Energetic Burden in Skeletal Myofibres of Patients With Heart Failure With Reduced Ejection Fraction.

Journal: Circulation. Heart failure

Published: May 06, 2026

Medical management of hypertrophic cardiomyopathy.

Medical management of hypertrophic cardiomyopathy.

Journal: Indian heart journal

Published: May 05, 2026

Beyond Glycogen Storage: AMPKγ2 Regulates Cardiac Hypertrophy and Electrophysiology via Myosin Interaction.

Beyond Glycogen Storage: AMPKγ2 Regulates Cardiac Hypertrophy and Electrophysiology via Myosin Interaction.

Journal: bioRxiv : the preprint server for biology

Published: May 04, 2026

Showing 1-12 of 556

Last Updated: 06/30/2026